Anixa Biosciences announces Japanese patent on breast cancer vaccine technology

Anixa Biosciences’ collaborator Cleveland Clinic has received a “Decision to Grant” notice from the Japan Patent Office for the patent application titled “Vaccine Adjuvants and Formulations.” The vaccine is currently being studied in a phase one clinical trial at Cleveland Clinic. This vaccine technology was invented in the Department of Inflammation and Immunity at Cleveland Clinic’s Lerner Research Institute. Cleveland Clinic exclusively licensed this technology to Anixa Biosciences.